By inhibiting cancer stem cells, capable of re-initiating cancer after remission, the Beljanski® extracts, Pao pereira and Rauwolfia vomitoria, limit the risk of recurrence. Two studies confirm this action on the stem cells of pancreatic cancer, one of the most difficult to cure.
To understand the importance of the studies discussed here, one must understand how cancer cells work. Two studies published in 2012 (1) made progress on this point. They confirmed that, in all types of cancer, not all cancer cells are created equal. Some have a more important role than others: they are in a way the masters of cancer. The researchers called them Cancer Stem Cells (CSCs). If these cells are not eliminated by treatments, the risk of recurrence after remission is greater because they can recreate cancer. However, these cells develop resistance to chemotherapy (2) and radiotherapy (3). What’s even worse, CSCs can reproduce and enrich the population of resistant cells (3).
Additionally, the effectiveness of a treatment is no longer measured only by the reduction of a tumor, but also by the elimination of these CSCs.
CSCs, Pet Peeves of Oncologists
Since 2012, CSCs have become the pet peeves of oncologists. This is why the researchers at Kansas University Medical Center (KUMC) who had previously worked with the Beljanski® extracts Pao pereira and Rauwolfia vomitoria, chose to test these extracts on cancer stem cells. They also chose one of the most difficult and undoubtedly the most dangerous cancers to treat: pancreatic cancer. They conducted in vitro studies on human cells and in vivo studies on mice, which are mandatory studies to do prior to human trials. These essays resulted in two publications in peer-reviewed scientific journals.
Rauwolfia Vomitoria: Beljanski's® Extract Inhibits Pancreatic CSCs
The first extract used was Rauwolfia vomitoria, an African plant whose anticancer molecules were identified and extracted by Dr. Mirko Beljanski, is available today under the name RovolV®. The study tested the Beljanski® extract of Rauwolfia vomitoria in mice with pancreatic cancer. All of the data collected throughout the study shows that Rauwolfia vomitoria inhibits pancreatic CSCs o in other words, neutralizes them. They also found that this extract did not have any negative side effects.
These results are all the more remarkable in that they contrast with the poor therapeutic results obtained by conventional treatments for pancreatic cancer, linked to resistant CSCs which promote metastasis and tumor return. The study, titled Inhibition of Pancreatic Cancer Stem Cells by Rauwolfia Vomitoria Extract, was published in December 2017 by the Oncology Reports.
This study therefore scientifically validates the numerous testimonies of patients cured of this type of cancer after having used products resulting from the research of Dr. Mirko Beljanski.
The Beljanski® Extract Pao Pereira Inhibits Pancreatic CSCs in vitro and in vivo
KUMC conducted a second study on pancreatic cancer, but this time with Pao pereira.
“We have studied the extract of the medicinal plant Pao pereira (Pao) for its activity against pancreatic CSCs. Pao inhibited the overall proliferation of human pancreatic cancer cell lines," said the authors in the study published in May 2018 in the Journal Integrative Cancer Therapies. As for the in vivo study titled Extract of the Medicinal Plant Pao Pereira Inhibits Pancreatic Cancer Stem-Like Cell In Vitro and In Vivo, they observed that CSCs were also inhibited in mice. Most importantly, the study showed that Pao pereira did not have any unwanted side effects.
Importance of Avoiding Recurrences in Pancreatic Cancer
Surprisingly enough, this information has not been taken into the mainstream scientific and medical community, even though research is now focused on eliminating CSCs. The relapse of pancreatic cancer is important: the rate of Metastatic recurrence is 70% according to the French National Society of Gastroenterology (4). In the event of recurrence, even if diagnosed quickly, the chances of recovery are limited, states the European Society for Medical Oncology (5).
Clearly, it is important to treat CSCs in the first cancer treatment. And these studies show the usefulness of recommending the two Beljanski® extracts to treat CSCs. And not just for pancreatic cancer because these extracts attack cancer cells regardless of the organ or gender, without any negative side effects!
Questions? We are here to answer them.
- Two studies were published on CHCs in 2012
- Mechanisms of resistance of cancer stem cells to chemotherapy https://www.em-consulte.com/en/article/1183496
- Effect of Radiation Therapy on Breast Cancer Cancer Stem Cells: Resistance, Reprogramming, and Treatments https://link.springer.com/article/10.1007/s10269-017-2699-8